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Abstract
Background: Pulmonary sarcoidosis is an inflammatory disease, characterized by an accumulation of CD4
+
lymphocytes and the formation of non-caseating epithelioid cell granulomas in the lungs. The disease either
resolves spontaneously or develops into a chronic disease with fibrosis. The neurotrophins nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) have been suggested to be important
mediators of inflammation and mediate tissue remodelling. In support of this, we have recently reported enhanced
NGF levels in the airways of patients with pulmonary sarcoidosis. However, less is known about levels of BDNF and
NT-3, and moreover, knowledge in the cellular sources of neurotrophins and the distribution of the corresponding
neurotrophin receptors in airway tissue in sarcoidosis is lacking.
Methods: The concentrations of NGF, BDNF and NT-3 in bronchoalveolar lavage fluid (BALF) of 41 patients with
newly diagnosed pulmonary sarcoidosis and 27 healthy controls were determined with ELISA. The localization of
neurotrophins and neurotrophin receptors were examined by immunohistochemistry on transbronchial lung
biopsies from sarcoidosis patients.
Results: The sarcoidosis patients showed significantly enhanced NT-3 and NGF levels in BALF, whereas BDNF was
undetectable in both patients and controls. NT-3 levels in BALF were found higher in patients with non-Löfgren
sarcoidosis as compared to patients with Löfgren’s syndrome, and in more advanced disease stage. Epithelioid cells
and multinucleated giant cells within the sarcoid granulomas showed marked immunoreactivity for NGF, BDNF and
NT-3. Also, immunoreactivity for the neurotrophin receptor TrkA, TrkB and TrkC, was found within the granulomas.
In addition, alveolar macrophages showed positive immunoreactivity for NGF, BDNF and NT-3 as well as for TrkA,
TrkB and TrkC.
Conclusions: This study provides evidence of enhanced neurotrophin levels locally within the airways of patients
with sarcoidosis. Findings suggest that sarcoid granuloma cells and alveolar macrophages are possible cellular
sources of, as well as targets for, neurotrophins in the airways of these patients.
Introduction
Sarcoidosis is an inflammatory granulomatous disease
which primarily affects the lungs. The disease is charac-
terized by an accumulation of CD4
+ lymphocytes and
the formation of non-caseating epithelioid cell granulo-
mas in the affected organs. The granuloma consists of
highly differentiated mononuclear phagocytes (epithe-
lioid cells and multinucleated giant cells) surrounded by
lymphocytes [1]. The disease either resolves sponta-
neously or develops into a more chronic disease where
the sarcoid granulomas develop fibrotic changes, which
in the airways may lead to a progressive loss of lung
function. Factors that influence granuloma formation
and the development of fibrosis are not well understood
in sarcoidosis [2]. Löfgren’ss y n d r o m ei saf o r mo fs a r -
coidosis, which affects about 1/3 of Scandinavian
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onset of disease with fever, bilateral lymphadenopathy,
erythema nodosum and/or ankle arthritis [3]. Löfgren’s
syndrome is mostly associated with complete disease
resolution, often within two years, without the need of
any treatment while an insidious onset (non-Löfgren
sarcoidosis) is accompanied with a higher risk of devel-
oping chronic disease with progressive fibrosis of the
lungs.
We have recently reported higher levels of nerve
growth factor (NGF) in the airways of patients with
sarcoidosis as compared to healthy subjects [4]. NGF,
brain-derived neurotrophic factor (BDNF) and neurotro-
phin-3 (NT-3) belong to the family of neurotrophins,
and are structurally and functionally related mediators.
Neurotrophins are essential survival factors for nerve
cells and are critical for the development of peripheral
sensory neurons [5]. However, neurotrophins and
their corresponding receptors are not only expressed
within the nervous system, but are also present in non-
neuronal cells and in the airways [6,7]. Structural cells,
like epithelial and smooth muscle cells [6-8], and
immune cells, such as mast cells, eosinophils and lym-
phocytes [9-11], express neurotrophins as well as their
receptors. NGF has been immunolocalized to fibrotic
tissue in the lungs and found in elevated levels in spu-
tum from patients with interstitial pulmonary fibrosis
(IPF) [12-14]. Several studies have shown that neurotro-
phins have tissue healing properties, and are able to pro-
mote tissue remodelling in airway disease [8,14,15]. In
addition, neurotrophins seem to have pro-inflammatory
properties and mediate effects such as mast cell survival
and degranulation [16], eosinophil chemotaxis [17] and
lymphocyte activation [18,19]. In this context, neurotro-
p h i n sh a v eb e e ns h o w nt op l a yar o l ei np u l m o n a r y
inflammation in asthma [20]. Increased levels of NGF,
BDNF and NT-3 have been found in asthmatic airways
and are closely linked to airway hyper responsiveness
[6,18,21,22].
While knowing that NGF is elevated in bronchoalveo-
lar lavage fluid (BALF) of patients with pulmonary sar-
coidosis, less is known about the neurotrophins BDNF
and NT-3. Moreover the cellular sources of neurotro-
phins and the distribution of the corresponding neuro-
trophin receptors in the airways of these patients are
poorly understood.
The aim of the present study was to compare the con-
centrations of the neurotrophins NGF, BDNF and NT-3
in BALF of patients with newly diagnosed pulmonary
sarcoidosis with those of healthy controls. Furthermore,
the aim was to identify the localization of neurotrophins,
and the corresponding neurotrophin receptors, within
the sarcoid lung tissue.
Methods
Subjects
This study included 41 patients with newly diagnosed
sarcoidosis (4 current smokers, 10 ex-smokers, 27
never-smokers). All subjects had a typical clinical and
radiographic picture compatible with the disease in
addition to an elevated bronchoalveolar lavage (BAL)
CD4/CD8 ratio and/or a biopsy showing non-caseating
epithelioid cell granulomas. Diagnosis was established
according to defined criteria set up by the World Asso-
ciation of Sarcoidosis and other Granulomatous Disor-
ders (WASOG) [1]. Twentysix of the patients were
diagnosed with Löfgren’s syndrome [3]. Twentyseven
never-smoking healthy volunteers with normal chest
radiographs were included as healthy controls. No sub-
ject received corticosteroids at the time of BAL and
blood (serum) sampling. Paired blood and BAL samples
were obtained from 37 of the sarcoidosis patients and
from all healthy subjects. Clinical characteristics are pre-
sented in Table 1.
For immunohistochemistry, biopsy specimens showing
non-caseating epithelioid cell granuloma formation com-
patible with sarcoidosis were collected from 19 addi-
tional sarcoidosis patients, diagnosed according to the
above defined criteria. In 17 cases the biopsies were
transbronchial, in one patient lung tissue was sampled
through video-assisted thoracoscopy, and in one case an
intrathoracic lymph node biopsy was obtained during
mediastinoscopy. Four of the patients were current smo-
kers, 2 ex-smokers, and 13 were never-smokers. Seven
of the patients had Löfgren’s syndrome.
Bronchoscopy, including BAL (see below) and biopsy
sampling, were performed in all patients as they were
referred to the lung clinic at Karolinska University Hos-
pital in Stockholm, Sweden, for diagnostic purposes.
The study was approved by the Regional Ethical Review
Board in Stockholm (http://www.epn.se) (Dnr: 2005/
1031-31) and in accordance with the Helsinki Declara-
tion. All subjects gave their written informed consent.
Fiberoptic bronchoscopy
BAL of sarcoidosis patients and healthy subjects was
performed as previously described [23]. Briefly, a flexible
fiberoptic bronchoscope (Olympus Optical Co., Japan)
was wedged into a middle-lobe bronchus and five ali-
quots of 50 ml sterile PBS solution were instilled and
re-aspirated. Recovered BAL fluid (BALF) was separated
into a cell- and debris free BALF, which was stored
at 70°C until analyzed, and a cell fraction from which
cytospin slides for differential cell counts were prepared
and analyzed as previously described [23]. Biopsies were
fixed in a buffered 10% formalin solution for 24 h and
embedded in paraffin.
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Neurotrophins were quantified in BALF and serum by
commercially available, two-site enzyme-linked immu-
nosorbent assay (ELISA)-kits according to the manufac-
turer’si n s t r u c t i o n s( P r o m e g a ,U S A )a n da sp r e v i o u s l y
described [12,21]. Detection limit was 4.7 pg/ml for NT-
3 and 7.8 pg/ml for NGF and BDNF ELISA kits. All
samples were analyzed in duplicates and serum samples
were diluted in PBS before analysis (1:100 for NT-3 ana-
lysis and 1:500 for BDNF analysis).
Immunohistochemistry
Serial 4 μm thick sections were mounted on slides and
processed for immunohistochemistry. Sections were
deparaffinized in xylene, stepwise rehydrated through
graded ethanol, and antigen retrieval was achieved by boil-
ing slides in 10 mM citrate buffer (pH 6.0) (for neurotro-
phins and neurotrophin receptors) or ethylenediamine
tetraacetic acid (EDTA) buffer (pH 9.0) (for CD68) for
20 min in microwave oven. After cooling and washing in
PBS, slides were incubated in 0.3% H2O2 for 30 minutes to
block endogenous peroxidase activity. After blocking with
5% goat serum or horse serum (for CD68) for 1 h at room
temperature, slides were exposed to primary antibodies
diluted in blocking buffer over night at 4°C. Primary anti-
bodies and dilutions are presented in Table 2. In control
experiments, primary antibodies were omitted. Non-
specific binding of anti-NGF, -BDNF, -NT-3, -TrkA, TrkC
and TrkB was evaluated by incubating slides with the anti-
bodies pre-adsorbed with the corresponding blocking pep-
tides (ratio 1:5) (Santa Cruz Biotechnology Inc, Santa
Cruz, CA, USA). After incubation, slides were washed and
exposed to relevant biotinylated secondary antibodies
(goat anti-rabbit or horse anti-mouse) (1:300) (Vector
Laboratories, Burlingame, CA, USA) for 1 h at room
temp. The product of immune reaction was revealed using
Vectastain®, Elite®, ABC Kit (Vector Laboratories) followed
by SIGMA FAST™ 3,3 diaminobenzidine (Sigma-Aldrich,
St. Louis, MO, USA). Sections were then counter-stained
with Mayer’s hematoxylin before they were dehydrated,
mounted and viewed under light microscope (Leica
DMLB) at a magnification of ×100, ×200 and/or ×400.
Statistical analysis
Data are presented as medians (interquartile range).
Mann-Whitney test, or Kruskal-Wallis test followed by
Dunn’s post test, were used for group comparisons.
A p-value < 0.05 was considered significant. Analyses
were performed with Graphpad Prism 4.03 (Graphpad
Software Inc., USA).
Results
BAL analysis and differential cell counts
BAL recovery was higher in healthy subjects as compared
to sarcoidosis patients (78; 68-79% vs. 68; 60-75%, p <
0.05). BAL cell viability was similar in both healthy sub-
jects and sarcoidosis patients (median: 95%). BAL differen-
tial cell counts are presented in Table 3. In BALF, the total
cell concentration as well as concentrations of macro-
phages, lymphocytes and neutrophils were significantly
higher in sarcoidosis patients as compared to healthy sub-
jects. As expected, the percentage of macrophages was
lower and the percentage of lymphocytes was higher in
sarcoidosis patients compared to healthy subjects.
Neurotrophin levels in BALF
Significantly elevated concentration of NT-3 was found
i nB A L Ff r o ms a r c o i d o s i sp a t i e n t sa sc o m p a r e dt o
Table 1 Clinical characteristics of study subjects included for bronchoalveolar lavage studies
Sarcoidosis patients
Healthy subjects Sarcoidosis patients Löfgren’s syndrome Non-Löfgren
Subjects, n 27 41 26 15
Sex, (M/F) 11/16 26/15 12/14 12/3
Age, yr 30 (24-39) 37 (31-41) 36 (29-41) 38 (32-42)
Radiograph stage, (I/II/III/IV) - 22/16/3/0 16/10/0/0 6/6/3/0
Pulmonary function tests, %
VC 99 (94-106) 95 (83-104) 97 (84-105) 91 (79-101)
FEV1 99 (92-108)* 91 (86-99) 90 (86-102) 95 (77-101)
Data are presented as medians (interquartile ranges). M, male; F, female; VC, vital capacity; FEV1, forced expiratory volume in 1 s.
*; p < 0.05 versus sarcoidosis
patients.
Table 2 Anti-human antibodies used for
immunohistochemical staining
Antibody Cat No Source Dilution Manufacturer
NGF sc-548 rabbit 1:100 Santa Cruz Biotech. Inc
BDNF sc-546 rabbit 1:100 Santa Cruz Biotech. Inc
NT-3 sc-547 rabbit 1:100 Santa Cruz Biotech. Inc
TrkA sc-118 rabbit 1:100 Santa Cruz Biotech. Inc
TrkB sc-12 rabbit 1:100 Santa Cruz Biotech. Inc
TrkC sc-117 rabbit 1:100 Santa Cruz Biotech. Inc
CD68 M 0876 mouse 1:200 DakoCytomation
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sarcoidosis patients, significantly higher levels of NT-3
were found in BALF from patients with non-Löfgren
sarcoidosis compared to patients with Löfgren’s
syndrome (Figure 1B). In addition, higher NT-3 levels
were associated with more advanced disease stage
(Figure 1C). In line with our previous report [4], NGF
was significantly elevated in sarcoidosis patients (14.8;
6.1-22.6 pg/ml) as compared to healthy subjects (4.7;
2.0-17.0 pg/ml) (p < 0.01). In the present material, NGF
showed no significant association with Löfgren’ss y n -
d r o m eo rd i s e a s es t a g e .B D N Fi nB A L Fw a sb e l o wt h e
detection limit of the ELISA kit.
Neurotrophin levels in serum
No significant differences were found in NT-3 or BDNF
concentrations between patients and controls or between
subgroups of sarcoidosis patients. The concentration of
NT-3 was approximately 3000 times higher in serum (41;
22-79 ng/ml) compared to BALF (13.0; 10.0-19.3 pg/ml).
BDNF concentration in serum was 16; 12-24 ng/ml. NGF
levels in serum were not determined as the levels have pre-
viously been reported by us to be below detection limit [4].
Neurotrophin and neurotrophin receptor expression in
sarcoid lung tissue
Serial sections from 18 lung biopsies and one lymph
node biopsy were analyzed for NGF, BDNF, NT-3,
TrkA, TrkB and TrkC, respectively, by immunohisto-
chemistry. Figures 2, 3, 4 and 5 show representative
immunostainings.
The lung biopsies from sarcoidosis patients contained
typical non-necrotizing granulomas composed of epithe-
lioid cells and multinucleated giant cells and a sur-
rounding layer of lymphocytes (Figure 2A). Strong
immunoreactivity for CD68 (commonly used as a mar-
ker for monocyte and macrophage-derived cells) was
found in macrophage-like cells, epithelioid cells and
multinucleated giant cells (Figures 2B and 2C).
Marked NGF, BDNF and NT-3 immunoreactivity
was observed in the granulomas and was localized to
epithelioid cells and giant cells within the granulomas
(Figures 3A, B and 3C). No or less immunoreactivity for
NGF, BDNF or NT-3 was found within fibrotic tissue
around granulomas (Figures 3A, B and 3C). Analysing
neurotrophin receptor immunoreactivity in the tissue
sections, marked TrkA, TrkB and TrkC immunoreactiv-
ity was observed within the granulomas (Figures 3D, E
and 3F). Also immunoreactivi t yf o rt h en e u r o t r o p h i n s
and their receptors was found in inflammatory cells sur-
rounding the granulomas (Figure 3A and not shown).
Sarcoid granulomas in the mediastinal lymph node
also showed positive immunoreactivity for NGF, BDNF,
NT-3, TrkA, TrkB and TrkC, localized to the granulo-
mas and the surrounding lymphoid tissue (Figures 4A,
B, C, D, E and 4F).
Two of the lung biopsies contained ciliated bronchial
epithelium and submucosa. Marked immunoreactivity
f o rN G F ,B D N F ,N T - 3 ,T r k Aa n dT r k B ,a n dw e a k e r
immunoreactivity for TrkC was found in the epithelium
( F i g u r e s5 A ,B ,C ,D ,Ea n d5 F ) .S m o o t hm u s c l ec e l l si n
the submucosa showed immunoreactivity for NGF,
NT-3 and TrkA (Figures 5A, B and 5D) and infiltrating
inflammatory cells in the submucosa showed positive
immunostaining for NGF, BDNF, NT-3, TrkA and TrkB
(Figures 5A, B, C, D and 5F).
Marked immunoreactivity for NGF, BDNF, NT-3 as well
as for TrkA, TrkB and TrkC was observed in alveolar
macrophages (Figures 5G, H, I, J, K and 5L). The wall of
the alveoli displayed positive immunoreactivity for NT-3,
BDNF and TrkB (Figures 5H, I and 5L) and weaker immu-
noreactivity for NGF and TrkA (Figures 5G and 5J). TrkC
immunoreactivity was not observed within the alveolar
wall (Figure 5K).
Table 3 Differential cell counts in bronchoalveolar lavage
Sarcoidosis patients
Healthy subjects Sarcoidosis patients Löfgren’s syndrome Non-Löfgren
Total cell conc. *10
6/L 81 (62-94) *** 201 (133-308) 188 (131-308) 252 (132-319)
Macrophages % 94 (91-95) *** 75 (63-84) 77 (63-86) 69 (60-80)
Macrophages *10
6/L 75 (58-92) *** 143 (90-210) 141 (85-230) 165 (91-200)
Lymphocytes % 5.2 (3.8-7.0) *** 23 (14-34) 22 (13-33)
# 29 (19-40)
Lymphocytes *10
6/L 4.4 (2.7-6.1) *** 45 (22-81) 41 (15-76) 54 (36-87)
Eosinophils % 0 (0-0.2) 0.0 (0-0.7) 0.1 (0-0.6) 0.0 (0-1.0)
Eosinophils *10
6/L 0 (0-0.2) 0.0 (0-1.2) 0.2 (0-1.2) 0.0 (0-1.6)
Neutrophils % 1.0 (0.4-1.4) 1.0 (0.6-1.8) 1.4 (0.5-2.1)
# 0.6 (0.6-1.0)
Neutrophils *10
6/L 0.7 (0.3-1.1)*** 2.3 (0.9-3.5) 2.6 (1.2-4.1) 1.5 (0.9-2.6)
CD4/CD8 ratio ND 7.3 (4.2-11) 8.2 (4.9-14) 6.9 (3.8-9.8)
Data are presented as medians (interquartile ranges). ND: not determined. ***; p < 0.001 versus sarcoidosis patients,
#; p < 0.05 versus non-Löfgren.
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and non-Löfgren sarcoidosis showed similar localization
and strength of immunoreactivity for the different neu-
rotrophins and corresponding receptors (not shown).
Discussion
The present study provides evidence for increased levels
of the neurotrophins NT-3 and NGF locally in the
airways of patients with pulmonary sarcoidosis as com-
pared to healthy individuals. This study also describes,
for the first time, neurotrophin and neurotrophin recep-
tor expression localization in sarcoid granulomas within
the lungs and lymph nodes of patients with pulmonary
sarcoidosis. We have previously reported elevation of
NGF in BALF of sarcoidosis patients [4], and this study
confirms those results, and extends them by including
the analysis of the neurotrophins NT-3 and BDNF in
both BALF and serum, and by identifying cellular
s o u r c e so f ,a n dt a r g e t sf o r ,N G F ,B D N Fa n dN T - 3i n
the lungs of sarcoidosis patients.
This study shows that not only the NGF protein, but
also NT-3 protein, was elevated in BALF from sarcoido-
sis patients as compared to healthy subjects, while
BDNF protein levels were undetectable in both healthy
subjects and sarcoidosis patients. Sarcoidosis patients
presenting Löfgren’s syndrome have an acute disease
onset and often a favorable prognosis with high rate of
spontaneous disease resolution. In contrast, patients
with non-Löfgren sarcoidosis run a higher risk of devel-
oping chronic disease with lung fibrosis. In this study
we sub-grouped the sarcoidosis patients into those with
Löfgren’s syndrome and those with non-Löfgren sarcoi-
dosis, and we could show that the levels of NT-3 were
significantly higher in BALF in the non-Löfgren sarcoi-
dosis group. Differences between subgroups of sarcoido-
sis patients was not seen for NGF in this study, but has
been indicated in one of our previous studies, including
a larger study population [4]. Chest radiographic staging
(stage 0-IV) is a measurement of lung involvement in
sarcoidosis and reflects disease severity, where stage 0
describes no visible intrathoracic findings and stage IV,
being the most advanced stage, is characterized by pul-
monary fibrosis. When sub-grouping the patients
according to their radiographic stage, we found higher
NT-3 levels in BALF in patients with more advances
disease stage. Taken together, these results suggest an
association between NT-3 and disease severity and prog-
nosis and it could be speculated on whether NT-3 could
serve as an early clinical marker for disease activity and
progression in sarcoidosis.
In contrast to some other studies [24], BDNF was not
possible to detect in BALF in our study. A plausible rea-
son for this would be the difference in age of study par-
ticipants, different exposure to environmental factors
that may influence neurotrophin production and the
fact that we used higher lavage volumes. The latter
would dilute any acellular component to a larger degree.
Apart from our study, also other studies have shown
that the content of BDNF in BALF is near or below
detection limit of the used ELISA kit [21].
In serum, concentrations of BDNF and NT-3 of
healthy and sarcoidosis patients did not differ between
Figure 1 Neurotrophin-3 (NT-3) levels are increased in
sarcoidosis. NT-3 protein levels in bronchoalveolar lavage fluid
(BALF) from healthy subjects and patients with sarcoidosis (A), and
in subgroups of sarcoidosis patients divided according to Löfgren’s
syndrome or not (B) and radiographic stage (C). Horizontal bars
indicate median values. *: p < 0.05, **: p < 0.01.
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others have shown that NGF concentration in serum is
low or under the detection limit [4,25]. This supports
the concept of a local enhancement and a possible local
origin of neurotrophins in pulmonary sarcoidosis.
To elucidate the possible cellular sources of neurotro-
phins in the airways in sarcoidosis we performed immuno-
histochemistry on lung biopsy sections from distal airways
of sarcoidosis patients. An intense immunostaining for
NGF, BDNF and NT-3 was localized to granulomas and
Figure 2 Lung biopsy sections of sarcoidosis patients. The presence of non-caseating epithelioid cell granulomas (Gr) with a surrounding
layer of lymphocytes (hematoxylin-eosin staining, ×10) is shown in A). CD68 immunostaining in alveolar macrophages (AM), epithelioid cells (Ec)
(×10) is shown in B) and CD68 immunostaining in a multinucleated Giant cell (Gc) and epithelioid cells (Ec) (×40) is shown in C).
Figure 3 Neurotrophin and neurotrophin receptor immunostaining in sarcoid lung granulomas. Immunostainings for NGF (A), NT-3
(B), BDNF (C), TrkA (D), TrkC (E) and TrkB (F) on lung biopsy sections from sarcoidosis patients (×40). Positive immunostaining was localized to
epitheioid cells and Giant cells within the granulomas. F: fibrosis; Ic: infiltrating inflammatory cells. Non-specific (NS) immunostaining is shown in
(G) and was obtained by exposing the sections to the antibodies preabsorbed with the corresponding blocking peptide (×20).
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granulomas. Epithelioid cells are macrophage-derived,
highly differentiated cells with secretory functions and
giant cells are multinucleated cells resulting from fusion of
epithelioid cells. To our knowledge, this is the first report
on neurotrophin expression in these cells and we suggest
that they are possible cellular sources of the enhanced
NGF and NT-3 levels detected in the bronchoalveolar
lavage fluid. In our study we also had access to one pul-
monary draining lymph node obtained with mediastino-
scopy from a patient with pulmonary sarcoidosis. The
lymphoid tissue exhibited marked granuloma formations,
which were immunopositive for NGF, BDNF and NT-3.
Previous reports have shown that infection-induced hepa-
tic- and brain granulomas produce NGF, and that
enhanced levels of NGF can be detected in granulomatous
tissue [26-28]. Also an infectious cause has been suggested
in the pathogenesis of sarcoidosis and in sarcoid granu-
loma formation [1].
NGF, BDNF and NT-3 immunostainings were also
detected in structural- and inflammatory cells in sarcoid
lung biopsies, as supported by previous studies in
healthy and asthmatic airways [6,7]. Interestingly,
in vitro studies on airway structural cells, such as
epithelial cells, fibroblasts and smooth muscle cells, have
shown that these cells produce neurotrophins constitu-
tively and that the production is enhanced under inflam-
matory conditions [29-31]. In addition, Ricci and
co-workers have demonstrated that immune cells, such
as alveolar macrophages and T-lymphocytes, retrieved
from BAL from sarcoidosis patients, express NGF, NT-3
and BDNF to a larger degree than BAL cells from
healthy subjects [32]. We confirm and extend these
results by showing positive NGF, BDNF and NT-3
Figure 4 Neurotrophin and neurotrophin receptor immunostaining in sarcoid lymph node granulomas. Immunostainings for NGF (A),
NT-3 (B), BDNF (C), TrkA (D), TrkC (E) and TrkB (F) on sections of a mediastinal lymph node from a patient with sarcoidosis (×20). Positive
immunostaining was localized to the granulomas. Non-specific (NS) immunostaining is shown in G) and was obtained by exposing the sections
to the antibodies preabsorbed with the corresponding blocking peptide.
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Page 7 of 11Figure 5 Neurotrophin and neurotrophin receptor immunostaining in sarcoid lung tissue. Immunostainings for NGF (A, G), NT-3 (B, H),
BDNF (C, I), TrkA (D, J), TrkC (E, K) and TrkB (F, L) on lung biopsy sections from sarcoidosis patients (×20). Ep: epithelium, Sm: smooth muscle, Ic:
infiltrating inflammatory cells and AM: alveolar macrophages. Non-specific (NS) immunostainings are shown in (M & N) and were obtained by
exposing the sections to the antibodies preabsorbed with the corresponding blocking peptide.
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the lung parenchyma of sarcoidosis patients. It is well
known that T-lymphocytes and macrophages infiltrate
the lungs in sarcoidosis patients, and therefore it may be
postulated that an increased number of neurotrophin-
expressing inflammatory cells, and specifically alveolar
macrophages, in sarcoidosisp a t i e n t sc o n t r i b u t et o
enhanced levels of neurotrophins in BALF of these
patients. Thus, we have identified multiple sources of
neurotrophins in sarcoidosis airways, where the granulo-
mas seem to be a unique source.
To elucidate the cellular targets for NGF, BDNF and
NT-3 within the airways in sarcoidosis, we studied the
presence of the corresponding neurotrophin receptors,
TrkA, TrkB and TrkC, in lung biopsies. TrkA, TrkB and
TrkC belong to the protein tyrosine kinase (Trk) family
of receptors, which bind neurotrophins with high affi-
nity. While TrkA is the primary receptor for NGF [33],
TrkB is the primary receptor for BDNF [34] and TrkC
is the primary receptor for NT-3 [35]. We found that
the sarcoid lung granulomas were immunoreactive for
both TrkA, TrkB and TrkC, indicating that neurotro-
phins, which are also produced within the granulomas,
are able to function in an autocrine and/or paracrine
manner in the granuloma microenvironment in lung tis-
sue in sarcoidosis. Similarly, granulomas in the mediast-
inal lymph node were positive for the two neurotrophin
receptors arguing for a possible local role of neurotro-
phins also in lymphoid tissue. In addition, we demon-
strated TrkA, TrkB and TrkC immunoreactivity in
structural cells in sarcoid biopsies, in line with previous
studies in healthy airways [7,8,36]. As described pre-
viously in both healthy and sarcoid airways, we also
observe neurotrophin receptor immunoreactivity in
alveolar macrophages [32,37]. Taken together, the cur-
rent findings suggest that, besides the granulomas, also
structural- and inflammatory cells are possible targets
for the neurotrophins in the airways in sarcoidosis.
Despite the lack of detectable levels of BDNF in BALF,
we could detect both BDNF and its receptor in the
granulomas and airway cells in sarcoidosis by immuno-
histochemistry in a similar fashion as for NGF and
NT-3. This indicates that besides NGF and NT-3,
B D N Fc o u l db eam e s s e n g e rm o l e c u l eo fr e l e v a n c ei n
pulmonary sarcoidosis. Further studies are required to
support this hypothesis.
The functional roles of neurotrophins in inflammatory
conditions of the airways are considered to be multiple
and NGF is often referred to as an inflammatory media-
tor. Elevations of neurotrophins have previously been
described to be linked to pulmonary inflammatory dis-
eases, including asthma and interstitial pulmonary fibro-
sis (IPF). In asthma, neurotrophins have been described
to be elevated in BALF as compared to healthy subjects
[6,21] and to enhance airway inflammation and airway
hyperreactivity [22,38-40]. Importantly, airway hyper-
reactivity is not a specific feature for asthma only, but is
also present in patients with sarcoidosis [41]. In addi-
tion, a role for neurotrophins in wound healing and
fibrosis has been suggested [42]. Thus, neurotrophin
expression has been linked to airway tissue remodelling,
shown to be immunolocalized to fibrotic tissue in
patients with IPF [12,14], and found in increased levels
in sputum of these patients [13]. Furthermore, neurotro-
phins have been shown to modulate fibroblast migration
and pro-fibrotic phenotype [14,15]. Interestingly, we
found an association of higher NT-3 levels in subgroups
of sarcoidosis patients associated with a higher risk of
developing chronic disease and fibrosis. Whether neuro-
trophin expression in sarcoid granulomas may promote
the persistence of the granuloma and/or promote the
development of fibrosis needs to be further investigated.
In conclusion, the present study describes that the
neurotrophins NGF, BDNF and NT-3 are expressed in
sarcoid granulomas in the airways and that enhanced
levels of NGF and NT-3 are found in bronchoalveolar
lavage fluid of patients with pulmonary sarcoidosis as
compared to healthy individuals. The findings of immu-
noreactivity for TrkA, TrkB and TrkC, the high-affinity
receptors for NGF, BDNF and NT-3, respectively, within
granulomas, structural- and inflammatory cells, suggest
that these are possible cellular targets for the neurotro-
phins in sarcoid airways. Taken together, this study sup-
ports the concept that the neurotrophins are involved
airway inflammation, granuloma biology and fibrosis in
inflammatory pulmonary diseases.
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